TOXIC OIL SYNDROME AND EOSINOPHILIA-MYALGIA-SYNDROME - MAY 8-10, 1991, WORLD-HEALTH-ORGANIZATION MEETING REPORT

被引:46
作者
PHILEN, RM [1 ]
POSADA, M [1 ]
机构
[1] MINIST SANIDAD & CONSUMO, FONDO INVEST SANITARIA, SUBDIRECC GEN FORMAC & DIFUS INVEST, MADRID, SPAIN
关键词
EOSINOPHILIA-MYALGIA SYNDROME; L-TRYPTOPHAN; RAPESEED OIL; TOXIC OIL SYNDROME;
D O I
10.1016/S0049-0172(05)80017-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In May 1991, researchers and clinicians from throughout the world met at a workshop sponsored by the Regional Office for Europe of the World Health Organization in collaboration with the Fondo de Investigación Sanitaria, Spain, and the U.S. Food and Drug Administration, National Institutes of Health, National Institutes of Mental Health, and Centers for Disease Control and Prevention to share information about two very similar diseases-toxic oil syndrome and eosinophilia-myalgia syndrome. In this paper the interpretation of conference proceedings is presented, current knowledge of the two disorders is summarized, and some possible areas for future research are mentioned. Toxic oil syndrome and eosinophilia-myalgia syndrome have many similarities. Both are related to consumer products that were presumed to be safe but have been found to have numerous trace contaminants, many of which remain to be identified, including the etiologic agents of both disorders. Both illnesses affect patients clinically by causing intense, incapacitating myalgias and a marked peripheral eosinophilia. Other rheumatologic manifestations are common in both, including arthralgias, sicca syndrome, sclerodermalike skin changes, carpal tunnel syndrome, and joint contractures. No clinical or laboratory feature has been found to be pathognomonic of either disease, and accurate diagnosis rests on the clinical judgment of the attending physician. Deaths have occurred in both diseases, and the cumulative mortality for each is approximately 2.5% for the first 2 years. Long-term complications include pulmonary hypertension, peripheral neuropathies, and joint contractures. Although treatment with corticosteroids has resulted in significant symptomatic relief in persons with either disorder, it does not alter the clinical course or long-term outcome. Research into the etiologic agents, preferred treatments, and ways to avoid similar problems in the future is needed. © 1993 W.B. Saunders Company. All rights reserved.
引用
收藏
页码:104 / 124
页数:21
相关论文
共 135 条
[1]  
ALDAMIZ HO, 1988, REV CLIN ESP, V182, P71
[2]  
ALDRIDGE WN, 1991, WHO REGIONAL PUBLICA, V442, P63
[3]  
ALONSORUIZ A, 1984, LANCET, V2, P520
[4]   TOXIC OIL SYNDROME - A SYNDROME WITH FEATURES OVERLAPPING THOSE OF VARIOUS FORMS OF SCLERODERMA [J].
ALONSORUIZ, A ;
ZEAMENDOZA, AC ;
SALAZARVALLINAS, JM ;
ROCAMORARIPOLL, A ;
BELTRANGUTIERREZ, J .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 1986, 15 (03) :200-212
[5]  
ARNAIZVILLENA A, 1982, NEW ENGL J MED, V307, P1404
[6]  
BELL SA, 1992, J IMMUNOL, V148, P3369
[7]   AN INVESTIGATION OF THE CAUSE OF THE EOSINOPHILIA-MYALGIA SYNDROME ASSOCIATED WITH TRYPTOPHAN USE [J].
BELONGIA, EA ;
HEDBERG, CW ;
GLEICH, GJ ;
WHITE, KE ;
MAYENO, AN ;
LOEGERING, DA ;
DUNNETTE, SL ;
PIRIE, PL ;
MACDONALD, KL ;
OSTERHOLM, MT .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (06) :357-365
[8]   SYNTHESIS OF N-(5-VINYL-1,3-THIAZOLIDIN-2-YLIDENE)PHENYLAMINE AND ANALYSIS OF OILS IMPLICATED IN THE SPANISH TOXIC OIL SYNDROME FOR ITS PRESENCE [J].
BERNERT, JT ;
PENDERGRAST, AH ;
ASHLEY, DL ;
PATTERSON, DG ;
KILBOURNE, EM ;
ALEXANDER, LR ;
DELAPAZ, MP ;
BORDA, IA .
FOOD AND CHEMICAL TOXICOLOGY, 1989, 27 (03) :159-164
[9]   COMPOSITIONAL ANALYSIS OF OIL SAMPLES IMPLICATED IN THE SPANISH TOXIC OIL SYNDROME [J].
BERNERT, JT ;
KILBOURNE, EM ;
AKINS, JR ;
DELAPAZ, MP ;
MEREDITH, NK ;
BORDA, IA ;
WAGES, S .
JOURNAL OF FOOD SCIENCE, 1987, 52 (06) :1562-1569
[10]  
BLASCO R, 1992, CLIN EXP IMMUNOL, V89, P131